专职PI
王建华 研究员
研究员,博士生导师
E-mail: jianhuaw2007@qq.com
 

  王建华,博士,研究员,博士生导师,上海高校特聘教授(东方学者)及跟踪计划,上海市卫生局优秀学科带头人(新百人计划)。1994年毕业于安徽省蚌埠医学院医学检验专业,1997年和2002年分别获上海第二医科大学微生物专业硕士和生物化学与分子生物学专业博士学位,2003年在University of MichiganAnn Arbor, USA)从事博士后研究,20091月回国,任实验室PI。


研究领域:


  1.微环境在肿瘤发生发展中的作用及机制;
  2.前列腺癌微环境异质性机制及作用;
  3.表观遗传修饰高甲基化癌基因1HIC1)调控肿瘤发生发展。


研究团队:



代表性论著:

  1. Liang Y, Hou LD, Li LJ, Li L, Zhu LM, Wang Y, Huang X, Hou YC, Zhu DX, Zou HM, Gu Y, Weng XL, Wang YY, Li Y, Wu TQ, Yao MF, Gross I, Gaiddon C, Meng Luo M *, Wang JH*, Meng XJ*. Dichloroacetate restores colorectal cancer chemosensitivity through the p53/miR-149-3p/PDK2-mediated glucose metabolic pathway. Oncogene2019 Oct 9.
  2. Bian XJ, Xiao YT, Wu TQ, Yao MF, Du LL, Ren SC, Wang JH*. Microvesicles and chemokines in tumor microenvironment: mediators of intercellular communications in tumor progression. Molecular Cancer, 2019 Mar 30;18 (1):50.
  3. Li Y, Yao MF, Wu TQ, Zhang LY, Wang YY, Chen Y, Fu GH, Weng XL*, Wang JH*. Loss of hypermethylated in cancer 1 (HIC1) promotes lung cancer progression. Cellular Signalling, 2019; 53:162-169.
  4. Wang YY, Weng XL, Wang LY, Hao MG, Li Y, Hou LD, Liang Y, Wu TQ, Yao MF, Lin GW, Jiang YW, Fu GH, Hou ZY*, Meng XJ*, Lu JS*, Wang JH*. HIC1 deletion promotes breast cancer progression by activating tumor cell/fibroblast crosstalk. Journal of Clinical Investigation, 2018; 128(12):5235-5250.
  5. Hao MG, Weng XL, Wang YY, Sun XQ, Yan TT, Li Y, Hou LD, Meng XJ*, Wang JH*. Targeting CXCR7 improves the efficacy of breast cancer patients with tamoxifen therapy. Biochemical Pharmacology, 2018; 147:128-40.
  6. Hou LD, Zhu DX, Liang Y, Tian XH, Li L, Wang P, Zhu LM, Weng XL, Wang YY, Li Y, Wu TQ, Wang JH*, Meng XJ* . Identification of a specific peptide binding to colon cancer cells from a phage displayed peptide library. British Journal of Cancer, 2018; 118:79-87.
  7. HaoMG, Wang JL, Qin J, Ding YF, Sun XQ, Zu LD, Wang YY, Li Y, Chang K, Lin GW, Du JY,  Korinek V, Ye DW, Wang JH*. HIC1 loss promotes prostate cancer metastasis by triggering epithelial–mesenchymal transition. The Journal of Pathology, 2017; 242:409-20.
  8. Zhu DX, Hou LD, Hu B, Sun J, Wang JH*, Meng XJ*. Crosstalk among proteome, acetylome and succinylome in colon cancer HCT116 cell treated with sodium dichloroacetate. Scientific Reports, 2016; 6:37478-88.
  9. Zu LD, Xue YJ, Wang JL, Fu YJ, Wang XM, Xiao G, Hao MG, Sun XQ, Wang YY, Fu GH, Wang JH*. The feedback loop between miR-124 and TGF-β pathway plays a significant role on non-small cell lung cancer metastasis.Carcinogenesis, 2016; 37:333-43.
  10. Xiao G, Wang XM, Wang JL, Zu LD, Cheng GC, Hao MG, Sun XQ, Xue YQ, Lu JS*, Wang JH*. CXCL16/CXCR6 chemokine signaling mediates breast cancer progression by pERK1/2-dependent mechanisms. Oncotarget, 2015; 6:14165-78.
  11. Cheng GC, Sun XQ, Wang JL, Xiao G, Wang XM, Fan XM, Zu LD, HaoMG, Qu Q, Mao Y, Xue YJ, Wang JH*. HIC1 silencing in triple-negative breast cancer drives progression through misregulation of LCN2. Cancer Research, 2014; 74:862-72.
  12. Zheng JH, Wang JL, Sun XQ,Hao MG,Ding T, Xiong D, Wang XM, Zhu Z, Xiao G, Cheng GC, Zhao MZ, Zhang J, Wang JH*. HIC1 by epigenetic modification modulates prostate cancer progression. Clinical Cancer Research, 2013; 19:1400-10.
  13. Hao MG, Zheng JH, Hou KL, Wang JL, Chen XS, Lu XJ, Bo JJ, Xu C, Shen KW, Wang JH*. Role of chemokine receptor CXCR7 in bladder cancer progression. Biochemical Pharmacology, 2012; 84:2204-14.
  14. Tian QW, Tang MH, Sun YG, Zou RJ , Chen ZG, Zhu MF ,Yang SP , Wang JL, Wang JH, Hu JQ. Hydrophilic Flower-Like CuS Superstructures as an Effi cient 980 nm Laser-Driven Photothermal Agent for Ablation of Cancer Cells. Advanced Materials, 2011; 3:3542-47.
  15. Wang JH*, Ying GG, Wang JC, Jung YH, Lu J, Zhu J, Pienta KJ, Taichman RS. Characterization of phosphoglycerate kinase-1 expression by stromal cells derived from the tumor microenvironment in prostate cancer progression. Cancer Research, 2010; 70:471-48. (Co-corresponding author)
  16. Sun XQ, Chen GC, Hao MG, Zheng JH, Zhou XM, Zhang J, Taichman RS,Pienta KJ, Wang JH*. The role of CXCR12/CXCR4/CXCR7 chemokine axis in cancer progression. Cancer and Metastasis Reviews, 2010; 29:709-22.
  17. Wang JH*, Lu Y, Wang JC, Koch AE, Zhang J, Taichman. RS. CXCR6 induced prostate cancer progression by the AKT/mTOR signaling pathway. Cancer Research, 2008; 68:10367-76.(Co-corresponding author)
  18. Wang JH, Shiozawa Y, Wang J, Wang Y, Jung Y, Pienta KJ, Mehra R, Loberg R, Taichman RS. The role of CXCR7/RDC1 as a chemokine receptor for CXCL12 (SDF-1) in prostate cancer. Journal of Biological Chemistry, 2008; 283:4283-94.
  19. Wang JH, Wang JC, Dai JL, Jung YH, Wei CL, Wang Y, Havens A, Hogg PJ, Keller ET, Pienta KJ, Nor JE, Wang CY, Taichman RS. A glycolytic mechanism regulating an angiogenic switch in prostate cancer. Cancer Research, 2007; 67:149-59.
 
复旦大学肿瘤研究所 通讯地址: 东安路270号2号楼1312室 64175590-5312 Email:fuci2012@126.com
Copyright 2013 shca.org.cn All rights reserved. 复旦大学肿瘤研究所 版权所有